Mepolizumab demonstrates high clinical efficacy in both allergic and non-allergic Asthma

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-12-01T10:30:18+05:30 | Updated On 1 Dec 2022 1:05 PM IST

A new study revealed that mepolizumab is clinically very effective for the treatment of severe allergic and non-allergic phenotypes of asthma. The study results were published in the journal Annals of Allergy, Asthma, Immunology.

Mepolizumab's efficacy is based on eosinophilia, which serves as a basis for overlapping allergic and non-allergic asthma phenotypes. While the efficacy and safety of mepolizumab in severe asthma are well-known, there is limited data on the comparative effectiveness among allergic and non-allergic phenotypes of asthma. Hence researchers conducted a retrospective cohort study to compare the impact of treatment with mepolizumab on patients with allergic versus non-allergic asthma.

Also Read: 3-body wear of prefabricated and 3D-printed artificial denture teeth have good functionality

The study was carried out from January 2016–December 2019 using administrative claims data from Optum Research Database. Participants included patients having asthma for >=6 years and were initiated on mepolizumab. Both during the baseline period which was 12 months before mepolizumab initiation and during the follow-up period which is 12 after the initiation, asthma exacerbation rate and OCS use were assessed. Allergic status was ascertained using diagnosis codes, medication use and lab test results.

Results:

Eligibility criteria were met by a total of 240 (44.6%) allergic and 298 (55.4%) non-allergic asthma patients.
For both allergic asthma (3.19 to 2.10) and non-allergic asthma patients (2.51 to 1.70), the mean asthma exacerbation rate was significantly reduced from baseline to follow-up.
The mean count of OCS claims from baseline to follow-up has shown a significant reduction for patients with allergic (5.19 to 3.46) and non-allergic asthma (5.46 to 3.20).
There were no noticeable significant differences between cohorts in the decreases in asthma exacerbations or counts of OCS claims from baseline to follow-up.

Also Read: Patients with advanced proximal gastric cancer located at the posterior gastric wall may benefit from LSTG

Thus, the study shows the real-world effectiveness of Mepolizumab for the treatment of severe asthma with allergic and non-allergic phenotypes.

Further reading: Silver J, Steffens A, Chastek B, Deb A. Real-world effectiveness of mepolizumab in patients with allergic and non-allergic asthma. Ann Allergy Asthma Immunol. 2022;125(5):S42-43. doi: 10.1016/j.anai.2022.08.624

mepolizumabsevere asthmaallergic phenotypenon-allergic phenotypereal-world effectivenessEosinophilianon-allergic asthmaexacerbation

Source : Annals of Allergy, Asthma, Immunology

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751